Effect of no Drainage Tube on Blood Loss and Recovery After High Tibial Osteotomy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03954860 |
|
Recruitment Status :
Completed
First Posted : May 17, 2019
Last Update Posted : February 19, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Osteoarthritis, Knee | Other: Drainage Tube Drug: Tranexamic Acid Drug: Sodium Chloride 0.9% | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 80 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Effect of no Drainage Tube on Blood Loss and Recovery After High Tibial Osteotomy |
| Actual Study Start Date : | August 1, 2018 |
| Actual Primary Completion Date : | September 1, 2019 |
| Actual Study Completion Date : | September 1, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: No Drainage
The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. No drainage tube was placed after operation.
|
Drug: Tranexamic Acid
Tranexamic acid (TXA) is an anti-fibrinolytic drugcan,which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.
Other Name: TXA Drug: Sodium Chloride 0.9% Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .
Other Name: sodium chloride solution |
|
Active Comparator: Drainage
The preoperative dose of tranexamic acid was calculated according to 20 mg / kg body weight, 100 ml of tranexamic acid sodium chloride solution was dripped 30 minutes before operation, and 30 ml saline containing 2 g tranexamic acid was applied to the local area before loosening the tourniquet.Postoperative intravenous drip of 100 ML sodium chloride solution containing 20 mg / kg tranexamic acid. Drainage tube should be placed after operation.
|
Other: Drainage Tube
The drainage tube drainage to guide the pus, blood and liquid accumulated between human tissues or in body cavity outside the body of High tibial osteotomy'patients. Drug: Tranexamic Acid Tranexamic acid (TXA) is an anti-fibrinolytic drugcan,which can increase the stability of fibrin clots and achieve hemostasis for High tibial osteotomy'patients.
Other Name: TXA Drug: Sodium Chloride 0.9% Sodium Chloride 0.9% is a solution of sodium chloride, which has the same osmotic pressure as animal or human plasma in physiological experiments or clinics, and can be used to dilute Tranexamic Acid .
Other Name: sodium chloride solution |
- Postoperative blood loss [ Time Frame: The third day after operation ]Total blood loss preoperative blood volume =(preoperative hematocrit-postoperative Hematocrit) + transfusion volume.
- Haemoglobin [ Time Frame: The third day after operation ]Reactive blood loss
- Hematocrit [ Time Frame: The third day after operation ]Reactive blood loss
- Hospital for special surgery knee score [ Time Frame: postoperative 3 month ]HSS is a knee function scoring system with a full score of 100. 0 means the loss of knee function, 100 means the best knee function, and the greater the value, the better knee function.
- Visual Analogue Scale Postoperative Day One [ Time Frame: Postoperative Day One ]Draw a 10 cm horizontal line on the paper. One end of the line is 0, indicating no pain; the other end is 10, indicating severe pain; and the middle part indicates varying degrees of pain. The patient selects a point from the horizontal line and the length from 0 to this point is the Visual Analogue Scale score.
- Visual Analogue Scale Postoperative Day Three [ Time Frame: Postoperative Day Three ]Draw a 10 cm horizontal line on the paper. One end of the line is 0, indicating no pain; the other end is 10, indicating severe pain; and the middle part indicates varying degrees of pain. The patient selects a point from the horizontal line and the length from 0 to this point is the Visual Analogue Scale score.
- Visual Analogue Scale Postoperative Day Five [ Time Frame: Postoperative Day Five ]Draw a 10 cm horizontal line on the paper. One end of the line is 0, indicating no pain; the other end is 10, indicating severe pain; and the middle part indicates varying degrees of pain. The patient selects a point from the horizontal line and the length from 0 to this point is the Visual Analogue Scale score.
- Circumference of shank Postoperative Day One [ Time Frame: Postoperative Day One ]indirectly reflects the latent blood loss
- Circumference of shank Postoperative Day Three [ Time Frame: Postoperative Day Three ]indirectly reflects the latent blood loss
- Circumference of shank Postoperative Day Five [ Time Frame: Postoperative Day Five ]indirectly reflects the latent blood loss
- Number of blood transfusions [ Time Frame: Postoperative Day Three ]If the hemoglobin was <80 g/l, allogeneic blood was transfused, and the number of blood transfusions were recorded.0 means no blood transfusion, and the larger the number is, the more blood transfusion.The maximum number does not exceed the total number of patients
- Number of Incision infection [ Time Frame: postoperative 3 month ]The incision was red, swollen, hot and painful, and the blood routine showed that the leukocyte was increased.
- Number of hematoma formation [ Time Frame: postoperative 3 month ]After operation, the incision is swollen and has wave motion, but it is not hot or painful, and there will be blood outflow during puncture.
- Number of delayed healing of the incision. [ Time Frame: On the 14th day after operation ]On the 14th day after operation, the incision did not heal.
- Volume of drainage [ Time Frame: Postoperative Day One ]Reactive blood loss
- Activated partial thromboplastin time [ Time Frame: The third day after operation ]Assessment of coagulation function in patients
- Prothrombin time [ Time Frame: The third day after operation ]Assessment of exogenous coagulation system
- Concentration of D-dimer [ Time Frame: The third day after operation ]Assessment of thrombotic diseases
- Concentration of Fibrinogen [ Time Frame: The third day after operation ]Assessment of coagulation function in patients
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Simple knee medial compartment osteoarthritis High tibial osteotomy.
- With varus deformity, medial proximal tibia angle <85°
- Unilateral High tibial osteotomy
- informed consent: Participants must be able to understand and voluntarily sign a written informed consent and follow the research protocol and interview process
Exclusion Criteria:
- patients who underwent other knee surgery within 6 months
- Preoperative combined anemia (Hb<100g/l)
- Patients with severe cardiovascular, hepatic, renal and hematopoietic diseases
- Patient with preoperative coagulation abnormalities 5. Patients with allergies and patients allergic to TXA.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03954860
| China, Shandong | |
| Qilu hospital of Shandong University | |
| Jinan, Shandong, China, 250014 | |
| Study Chair: | Peilai Liu, Ph.D | Qilu Hospital of Shandong University |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Qilu Hospital of Shandong University |
| ClinicalTrials.gov Identifier: | NCT03954860 |
| Other Study ID Numbers: |
2019041 |
| First Posted: | May 17, 2019 Key Record Dates |
| Last Update Posted: | February 19, 2020 |
| Last Verified: | May 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | The datasets used and/or analysed during the current study are available from the overall study officials on reasonable request. |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Osteoarthritis, Knee Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |
Tranexamic Acid Antifibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action Hemostatics Coagulants |

